VANI at a glance
The past year
Chart−16.8% $1.14, close Nov 20
- From the highest close
- −28.8%
- Vs the 200-day average
- −7.5%
Short interest
History369,789 shares
- Of shares outstanding
- 0.41%
- Since the last report
- −11.4%
- Days to cover
- 2.0 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
Filings2 insiders bought
- Purchases
- 1
- On this week's list
- Yes
- Form 4s filed
- Nov 16 – Nov 22
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
VANI price history
Loading recent earnings…
Investment thesis
What must happen next
NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market.HoldingMateriality: High
The company describes itself as a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting subdermal drug implant candidates. If the delivery advantage is real, Vivani can create platform value; if convenience, safety, or efficacy is not clearly superior, commercialization and partnering power collapse.
Watch: Improved injectable or oral chronic-disease therapies reduce the adherence and convenience problem NanoPortal is meant to solve.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as a clinical-stage biopharmaceutical company developing miniature, ultra-long-acting subdermal drug implant candidates.
Open source ↗Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform.WeakeningMateriality: High
Cash was $16.232 million at FY2025 year-end. A successful milestone can finance the next stage on better terms; delays can force dilution or program cuts before the asset is de-risked.
Watch: A trial delay, FDA clinical hold, or additional preclinical requirement pushes milestones beyond available funding.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $16.232 million at FY2025 year-end.
Open source ↗Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value.WeakeningMateriality: Medium
GAAP annual revenue was $0 in FY2025. External validation can change the company from a cash-consuming R&D project into a financeable platform; absence of validation leaves shareholders exposed to burn and dilution.
Watch: Potential pharmaceutical partners choose internal long-acting formulations or established delivery technologies instead of NanoPortal.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $0 in FY2025.
Open source ↗A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs.HoldingMateriality: Medium
The company reported 36 employees as of March 26, 2026. Focused execution extends the odds of reaching value-inflecting data; unfocused spending shortens runway without proportionate de-risking.
Watch: Headcount or spending expands materially before clear clinical validation.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company reported 36 employees as of March 26, 2026.
Open source ↗Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders.WeakeningMateriality: Medium
Stockholders’ equity declined from $44.308 million at FY2022 year-end to $15.730 million at FY2025 year-end. Even if the platform works scientifically, per-share returns can disappoint if the company must sell too much equity before the value inflection.
Watch: An at-the-market program, PIPE, warrant-heavy financing, or reverse-split-linked issuance occurs before meaningful clinical validation.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity declined from $44.308 million at FY2022 year-end to $15.730 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market. If the delivery advantage is real, Vivani can create platform value; if convenience, safety, or efficacy is not clearly superior, commercialization and partnering power collapse.
Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform. A successful milestone can finance the next stage on better terms; delays can force dilution or program cuts before the asset is de-risked.
Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value. External validation can change the company from a cash-consuming R&D project into a financeable platform; absence of validation leaves shareholders exposed to burn and dilution.
A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs. Focused execution extends the odds of reaching value-inflecting data; unfocused spending shortens runway without proportionate de-risking.
Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders. Even if the platform works scientifically, per-share returns can disappoint if the company must sell too much equity before the value inflection.
All standing thesis claims
Original report summary
Vivani is a binary platform bet: NanoPortal implants must prove they can make chronic-drug delivery easier and more consistent before cash burn and dilution overwhelm the option value.
Bull case and bear case
Bull case and bear case for Vivani Medical
Where the evidence on Vivani Medical disagrees: Mixed on the latest evidence (Nov 21, 2026). Of its 5 thesis points, 2 holding and 3 weakening.
Bull case: what the evidence supports
NanoPortal must create a real patient and prescriber advantage—reversible, ultra-long-acting, near constant-rate delivery—over repeat injections or oral therapy, or Vivani has technology without a market.
A small clinical-stage organization must keep spending tightly aimed at the Biopharm platform’s highest-value milestones rather than dispersing capital across too many programs or infrastructure needs.
Bear case: what the evidence questions
Vivani must convert development work into clinical, regulatory, or partnering milestones before the cash runway erodes, because it has no operating cash inflow to self-fund the platform.
Because Vivani has no commercial revenue, the business model needs outside validation—clinical data, regulatory progress, or a development partner—before it can claim pricing power or durable enterprise value.
Current holders need future financing to be non-dilutive, partnered, or raised after value-creating milestones; repeated low-quality equity issuance would shift much of NanoPortal’s upside away from existing shareholders.
Thesis-Break Engine
Thesis-break watch · Vivani Medical
No break has crossed Vivani Medical’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Vivani Medical filed an SEC 8-K on 2026-11-16: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Vivani Medical filed an SEC 8-K on 2026-11-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Vivani Medical filed an SEC 8-K on 2026-10-30: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Improved injectable or oral chronic-disease therapies reduce the adherence and convenience problem NanoPortal is meant to solve.
- A trial delay, FDA clinical hold, or additional preclinical requirement pushes milestones beyond available funding.
- Potential pharmaceutical partners choose internal long-acting formulations or established delivery technologies instead of NanoPortal.
- Headcount or spending expands materially before clear clinical validation.
- An at-the-market program, PIPE, warrant-heavy financing, or reverse-split-linked issuance occurs before meaningful clinical validation.
VANI news
Loading headlines…
Financial statements
VANI income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
VANI: quick answers
- When does Vivani Medical (VANI) report earnings next?
- Vivani Medical's next results are projected for February 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 12, 2026. Earnings calendar
- What is VANI's short interest?
- As of October 30, 2026, 369,789 VANI shares were sold short, 0.41% of its shares outstanding, down 11.4% from the count before. At the stock's average daily volume that is 2.0 days to cover. FINRA publishes the count twice a month. VANI short interest history

